• 2017
  • A Phase I study of the pharmacokinetics, safety and tolerability of a novel tocopheryl phosphate mixture/oxymorphone transdermal patch system.

    Gavin PD, Simon LS, Schlagheck T, Smith AJ, Krishnarajah J.
    Pain Manag. 2017 Aug 17.[Epub ahead of print]

  • The effect of tocopheryl phosphates (TPM) on the development of atherosclerosis in apolipoprotein-e deficient mice.

    Libinaki R, Vinh A, Tesanovic-Klajic S, Widdop RE, Gaspari TA.
    Clin Exp Pharmacol Physiol. 2017 Jul 26.[Epub ahead of print]

  • Pharmacokinetics, safety and tolerability of a novel tocopheryl phosphate mixture/oxycodone transdermal patch system: a Phase I study.

    Gavin PD, Simon LS, Schlagheck T, Smith AJ, Shakib S.
    Pain Manag. 2017 Jul;7(4):243-253.

  • Transdermal oxycodone patch for the treatment of postherpetic neuralgia: a randomized, double-blind, controlled trial.

    Gavin PD, Tremper L, Smith A, Williams G, Brooker C.
    Pain Manag. 2017 Jul;7(4):255-267.

  • Tocopheryl phosphate mixture (TPM) as a novel lipid-based transdermal drug delivery carrier: formulation and evaluation.

    Gavin PD, El-Tamimy M, Keah HH, Boyd BJ.
    Drug Deliv Transl Res. 2017 Feb;7(1):53-65.

  • 2015
  • Topical application of a novel oxycodone gel formulation (tocopheryl phosphate mixture) in a rat model of peripheral inflammatory pain produces localized pain relief without significant systemic exposure.

    Smith MT, Wyse BD, Edwards SR, El-Tamimy M, Gaetano G, Gavin P.
    J Pharm Sci. 2015 Jul;104(7):2388-96.

  • 2010
  • Effect of tocopheryl phosphate on key biomarkers of inflammation: Implication in the reduction of atherosclerosis progression in a hypercholesterolaemic rabbit model.

    Libinaki R, Tesanovic S, Heal A, Nikolovski B, Vinh A, Widdop RE, Gaspari TA, Devaraj S, Ogru E.
    Clin Exp Pharmacol Physiol. 2010 May;37(5-6):587-92.

  • 2007
  • Subchronic oral toxicity study of mixed tocopheryl phosphates in rats.

    Gianello R, Hall WC, Kennepohl E, Libinaki R, Ogru E.
    Int J Toxicol. 2007 Sep-Oct;26(5):475-90.

  • 2006
  • Evaluation of the safety of mixed tocopheryl phosphates (MTP) — a formulation of alpha-tocopheryl phosphate plus alpha-di-tocopheryl phosphate.

    Libinaki R, Ogru E, Gianello R, Bolton L, Geytenbeek S.
    Food Chem Toxicol. 2006 Jul;44(7):916-32.

  • 2005
  • Alpha-tocopheryl phosphate: a novel, natural form of vitamin E.

    Gianello R, Libinaki R, Azzi A, Gavin PD, Negis Y, Zingg JM, Holt P, Keah HH, Griffey A, Smallridge A, West SM, Ogru E.
    Free Radic Biol Med. 2005 Oct 1;39(7):970-6.

  • On the existence of cellular tocopheryl phosphate, its synthesis, degradation and cellular roles: a hypothesis.

    Negis Y, Zingg JM, Ogru E, Gianello R, Libinaki R, Azzi A.
    IUBMB Life. 2005 Jan;57(1):23-5.

  • 2004
  • Modulation of cell proliferation and gene expression by alpha-tocopheryl phosphates: relevance to atherosclerosis and inflammation.

    Ogru E, Libinaki R, Gianello R, West S, Munteanu A, Zingg JM, Azzi A.
    Ann N Y Acad Sci. 2004 Dec;1031:405-11.

  • Modulation of cell proliferation and gene expression by alpha-tocopheryl phosphates: relevance to atherosclerosis and inflammation.

    Munteanu A, Zingg JM, Ogru E, Libinaki R, Gianello R, West S, Negis Y, Azzi A.
    Biochem Biophys Res Commun. 2004 May 21;318(1):311-6.